Moderna Inc. ($MRNA) Stock Forecast: Down 5.1% Today

What is Moderna Inc.?

Moderna (MRNA) is known for its innovative mRNA technology, with a focus on COVID-19 vaccines. The stock's performance is closely linked to updates in the biotech sector and vaccine advancements.

Why is Moderna Inc. going down?

MRNA stock is down 5.1% on Dec 11, 2024 16:03

• Investor focus may have shifted due to Novavax's announcement of a late-stage study on a COVID-19-flu combo and flu vaccines, potentially impacting Moderna's stock negatively.
• Options trading trends suggest a bearish sentiment from deep-pocketed investors towards Moderna, which could have contributed to the stock's decline.
• Market reaction indicates that investors are closely monitoring developments in the biotech and vaccine landscape, making them highly responsive to news affecting Moderna's competitive position.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines

Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines.

https://www.zacks.com/stock/news/2381947/nvax-starts-late-stage-study-on-covid-19-flu-combo-flu-vaccines

Unpacking the Latest Options Trading Trends in Moderna - Moderna ( NASDAQ:MRNA )

Deep-pocketed investors have adopted a bearish approach towards Moderna MRNA, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.

https://www.benzinga.com/insights/options/24/12/42417150/unpacking-the-latest-options-trading-trends-in-moderna

Trending Today

Ethena ($ENA) Crypto Forecast: Up 16.7% Today

Wormhole ($W) Crypto Forecast: Up 5.9% Today

Avalanche ($AVAX) Crypto Forecast: Down 7.3% Today

Arbitrum ($ARB) Crypto Forecast: Down 5.3% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.1% Today

Aave ($AAVE) Crypto Forecast: Down 5.3% Today

Filecoin ($FIL) Crypto Forecast: Down 5.3% Today

Litecoin ($LTC) Crypto Forecast: Down 5.5% Today

TRON ($TRX) Crypto Forecast: Down 5.0% Today

ApeCoin ($APE) Crypto Forecast: Down 5.2% Today

Moderna Inc. Price History

18.10.2024 - MRNA Stock was up 5.1%

• Moderna's stock saw an impressive rise today despite ongoing questions about vaccine safety and the appointment of Robert F. Kennedy Jr. for leadership in the Department of Health and Human Services.
• Market response appeared favorable, potentially due to Moderna's unwavering belief in its products and competence to manage political obstacles.
• Investors may have construed Moderna's ability to withstand political uncertainties as a mark of robustness and future sustainability, contributing to the positive market trend.
• Despite initial worries, Moderna's stock exhibited resilience and gained momentum, underscoring investor trust in the company's future outlook.

08.10.2024 - MRNA Stock was down 6.9%

• Moderna reported impressive Q3 earnings, beating revenue expectations and attributing the growth to higher sales of its updated COVID-19 vaccine in the U.S. This positive news should have ideally boosted the stock.
• The bearish sentiment from smart money betting against Moderna in options trading could have influenced the stock's downward movement, signaling concerns among deep-pocketed investors.
• The uncertainty surrounding the potential appointment of Robert F. Kennedy Jr. as a 'Health Czar' by President-elect Donald Trump, which could impact vaccine stocks like Moderna, might have added to the negative market sentiment.
• Despite the positive Q3 earnings and sales beat, the overshadowing concerns about vaccine demand slowdown and market share issues raised by analysts could have outweighed the good news, leading to the bearish movement in Moderna's stock today.

06.11.2024 - MRNA Stock was up 6.4%

• The positive sentiment surrounding Moderna's latest Covid-19 vaccine update possibly drove the stock's bullish movement, despite some reluctance among Hong Kong residents.
• Moderna's stock performance could have been influenced by its recent inclusion among the top 10 large-cap gainers last week, alongside companies like Rivian Automotive and Rocket Lab.
• Investor confidence in Moderna's ongoing success in the biotech industry, especially amidst global vaccination initiatives, likely played a role in today's strong stock performance.

26.10.2024 - MRNA Stock was down 5.5%

• Moderna's stock experienced a bearish movement today, possibly due to:
• Profit-taking by investors after a period of strong performance, as indicated by the bearish stance taken by significant traders in options trading.
• Concerns about the spread of a mutated bird flu case in California, which could increase the urgency for vaccine development and potentially impact Moderna's competitive position in the market.
• Market volatility and overall sentiment affecting biotech stocks, leading to a broader sell-off in the sector.

10.11.2024 - MRNA Stock was down 5.0%

• The downward trend in Moderna's stock price today may be linked to reports of hesitation among Hong Kong residents regarding the latest Covid-19 vaccine offered by the company. This apprehension could have sparked concerns among investors about the potential impact on Moderna's vaccine sales and revenue.
• Moreover, a shift in options trading activities towards a negative stance by affluent investors could have exacerbated the pessimistic sentiment surrounding Moderna's stock, contributing to the notable decline witnessed today.
• These combined factors likely influenced the bearish perspective on Moderna's stock, underscoring the significance of public perception and investor sentiment in shaping market dynamics, particularly within the pharmaceutical industry.

14.10.2024 - MRNA Stock was down 5.4%

• The bearish movement in Moderna's stock today can be attributed to the significant bearish stance taken by investors with large amounts of capital, as indicated by the options trading activity.
• Despite Moderna reporting better-than-expected third-quarter earnings, concerns about a slowdown in vaccine demand and potential market share issues have overshadowed the positive results, leading to a negative sentiment among investors.
• The market may be reacting to the shift in focus within the pharmaceutical industry towards oncology, diverting attention and capital away from COVID-19 vaccine manufacturers like Moderna.
• The increased bearish sentiment in Moderna's options market suggests that investors are cautious about the company's future prospects, possibly due to concerns about the sustainability of vaccine demand and potential competition in the market.

19.10.2024 - MRNA Stock was down 5.0%

• Moderna's stock saw a decline today despite the company's strong belief in the efficacy of its vaccines.
• Political worries regarding vaccine safety and the appointment of Robert F. Kennedy Jr. to head the Department of Health and Human Services might have influenced the negative market mood.
• Attention on Moderna's rivals and legal troubles encountered by other companies like Metagenomi (NASDAQ: MGX) could have impacted investor faith in Moderna's stock.
• All in all, the mix of political uncertainties and legal issues in the biotech industry likely affected Moderna's downward trend in the market today.

11.11.2024 - MRNA Stock was down 5.1%

• Investor focus may have shifted due to Novavax's announcement of a late-stage study on a COVID-19-flu combo and flu vaccines, potentially impacting Moderna's stock negatively.
• Options trading trends suggest a bearish sentiment from deep-pocketed investors towards Moderna, which could have contributed to the stock's decline.
• Market reaction indicates that investors are closely monitoring developments in the biotech and vaccine landscape, making them highly responsive to news affecting Moderna's competitive position.

15.10.2024 - MRNA Stock was down 12.4%

• Moderna's stock experienced a bearish movement today.
• The selection of Robert F. Kennedy Jr., a vaccine skeptic, as the next health secretary of the HHS under President-elect Donald Trump, caused vaccine stocks to fall, including Moderna.
• Despite Moderna's Q3 earnings beating expectations, concerns over vaccine demand slowdown and market share overshadowed the positive results, leading to a bearish sentiment among investors.
• The bearish stance taken by investors with significant capital on Moderna's options further contributed to the downward pressure on the stock.

15.10.2024 - MRNA Stock was down 7.1%

• Moderna's stock experienced a downward trend today, likely due to concerns arising from the appointment of a vaccine skeptic, Robert F. Kennedy Jr., to lead the HHS. There are fears regarding the impact on vaccine development and distribution.
• The pessimistic view on Moderna's options by investors holding substantial capital may have contributed to the decline in the stock, indicating skepticism about the company's future performance.
• Despite exceeding expectations in Q3 earnings, worries about diminishing vaccine demand and market share challenges may have dampened the positive results, leading to a negative market sentiment.
• The notable bearish activity in Moderna's options by well-funded investors reinforces the prevailing negative sentiment towards the stock, suggesting a cautious stance from market participants regarding the company's future prospects.

15.10.2024 - MRNA Stock was down 6.2%

• Moderna's stock price fell following concerns arising from the appointment of a vaccine skeptic to a key position in the government administration. The future regulatory environment for vaccines is now in question, prompting a negative market response.
• Investors with substantial capital took a bearish stance, evident in the options trading activity, exacerbating the downward trajectory of Moderna's stock.
• The market's reaction underscores the impact of uncertainties surrounding vaccine policies and potential regulatory hurdles under the new administration on Moderna's stock performance for the day.

21.10.2024 - MRNA Stock was up 5.4%

• The appearance of a mutated bird flu case in California has drawn attention to vaccine development companies, including Moderna. This development likely bolstered investor confidence in Moderna's ability to address new health threats effectively.
• Despite some bearish options trading activities, Moderna's overall positive performance can be linked to the company's ongoing faith in its vaccine technology, particularly amidst public concerns regarding vaccine safety and changes in health leadership.
• The unfavorable investor sentiment towards companies like Metagenomi (NASDAQ: MGX) following class action lawsuits and shareholder alerts may have shifted investor focus towards established players such as Moderna, contributing to its strong performance today.